Schroder Investment Management Group
VKTX icon

Schroder Investment Management Group’s Viking Therapeutics VKTX Stock Holding History

Schroder Investment Management Group’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-183,846
Closed -$5.5M – 1249
2026
Q1 		$5.5M Sell
183,846
-30,694
-14% -$987K ﹤0.01% 765
2025
Q4 		$7.58M Buy
214,540
+67,951
+46% +$2.41M 0.01% 681
2025
Q3 		$3.78M Sell
146,589
-172,713
-54% -$5.15M ﹤0.01% 821
2025
Q2 		$8.46M Buy
319,302
+150,470
+89% +$3.96M 0.01% 663
2025
Q1 		$4.33M Buy
168,832
+108,838
+181% +$3.44M ﹤0.01% 781
2024
Q4 		$2.39M Sell
59,994
-39,592
-40% -$2.26M ﹤0.01% 902
2024
Q3 		$6.14M Sell
99,586
-2,050
-2% -$120K 0.01% 753
2024
Q2 		$5.39M Buy
+101,636
New +$6.66M 0.01% 766

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Schroder Investment Management Group's VKTX Position: Q2 2026 in Review

Schroder Investment Management Group sold out of Viking Therapeutics (VKTX) in Q2 2026, closing a stake of 183,846 shares — an estimated $5.5M sold.

Schroder Investment Management Group first reported a position in VKTX in Q2 2024 and held it in 8 quarters. The position peaked at $8.46M in Q2 2025. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Schroder Investment Management Group reported no remaining Viking Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Schroder Investment Management Group sold 183,846 Viking Therapeutics shares in Q2 2026, an estimated $5.5M.
  • Schroder Investment Management Group first reported a position in Viking Therapeutics in Q2 2024 and held it in 8 quarters.
  • Schroder Investment Management Group's Viking Therapeutics position peaked at $8.46M in Q2 2025.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Schroder Investment Management Group's 13F filing for Q2 2026, filed 13 Aug 2026.